Prot #NU UC18B01: Phase Ib/II Open-Label Single Arm Study to Evaluate Safety and Efficacy of Tucatinib in Combination with Letrozole and Palbociclib in Subjects with Hormone Receptor Positive and HER2-Positive Metastatic Breast Cancer

Project: Research project

Project Details

StatusActive
Effective start/end date5/29/185/29/24

Funding

  • Criterium, Inc. (Prot #NU UC18B01)
  • Pfizer Inc. (Prot #NU UC18B01)